Anti-angiogenic effects of the water extract of HangAmDan (WEHAD), a Korean traditional medicine

Bang, Ji‐Young; Kim, Kyung-Soon; Kim, Eung-Yoon; Yoo, Hwa‐Seung; Lee, Yeon‐Weol; Cho, Chong-Kwan; Choi, Youngjin; Jeong, Hyun‐Ja; Kang, In‐Cheol

doi:10.1007/s11427-011-4144-3

Cited by 17 publications

(11 citation statements)

References 22 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we intend to enclose microarray data, proteome data and other kind of data achieved from systemic methods into our database in the near future. Moreover, many folk prescriptions and traditional medicine are effective to treat certain rare or severe diseases (20), and collecting those formulae or medicines will be an urgent task, as many of them could be missed without prompted collection. Our database will be expanded to record this kind of information also.…”

Section: Discussionmentioning

confidence: 99%

TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis

Xue¹,

Zhao²,

Zhang³

et al. 2012

Nucleic Acids Research

448

348

View full text Add to dashboard Cite

As an alternative to modern western medicine, Traditional Chinese Medicine (TCM) is receiving increasingly attention worldwide. Great efforts have been paid to TCM’s modernization, which tries to bridge the gap between TCM and modern western medicine. As TCM and modern western medicine share a common aspect at molecular level that the compound(s) perturb human’s dysfunction network and restore human normal physiological condition, the relationship between compounds (in herb, refer to ingredients) and their targets (proteins) should be the key factor to connect TCM and modern medicine. Accordingly, we construct this Traditional Chinese Medicine Integrated Database (TCMID, http://www.megabionet.org/tcmid/), which records TCM-related information collected from different resources and through text-mining method. To enlarge the scope of the TCMID, the data have been linked to common drug and disease databases, including Drugbank, OMIM and PubChem. Currently, our TCMID contains ∼47 000 prescriptions, 8159 herbs, 25 210 compounds, 6828 drugs, 3791 diseases and 17 521 related targets, which is the largest data set for related field. Our web-based software displays a network for integrative relationships between herbs and their treated diseases, the active ingredients and their targets, which will facilitate the study of combination therapy and understanding of the underlying mechanisms for TCM at molecular level.

show abstract

Section: Discussionmentioning

confidence: 99%

TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis

Xue¹,

Zhao²,

Zhang³

et al. 2012

Nucleic Acids Research

448

348

View full text Add to dashboard Cite

show abstract

“…HAD-B (Dunsan Oriental Hospital, Daejeon, Korea), an herbal formula consisting of Radix P. notoginseng, C. militaris, C. appendiculata, Radix P. ginseng, calculus bovis, I. batatas 'Margarita', B. carteri, and C. myrrha in powder form, was prepared as reported previously 12,13,16 and stored at -20°C until use.…”

Section: Preparation Of Had-bmentioning

confidence: 99%

“…12 Additionally, antiangiogenesis effects and inhibition of cancer cell proliferation and metastasis have been reported. 13 In particular, case reports observed with HAD have been selected as part of the National Cancer Institute's Best Case Series Program.…”

Section: Introduction Imentioning

confidence: 99%

“…57 HAD-B has shown efficacy in inhibiting migration and proliferation of human umbilical vein endothelial cells and limiting the formation of capillary tube structures. 13 Furthermore, HAD has been used for the treatment of solid tumors, including pancreatic, lung, colorectal, and stomach cancers, since its development in 1996. 58 Accordingly, it is proposed that the antiinflammatory activity of HAD-B strongly contributes to its anti-cancer property through functional suppression of tumor-associated macrophages, in addition to its direct anticancer activity.…”

mentioning

confidence: 99%

See 1 more Smart Citation

HangAmDan-B, an Ethnomedicinal Herbal Mixture, Suppresses Inflammatory Responses by Inhibiting Syk/NF-κB and JNK/ATF-2 Pathways

Moh

Kim

et al. 2013

Journal of Medicinal Food

Self Cite

View full text Add to dashboard Cite

HangAmDan-B (HAD-B) is a powdered mixture of eight ethnopharmacologically characterized folk medicines that is prescribed for solid masses and cancers in Korea. In view of the finding that macrophage-mediated inflammation is a pathophysiologically important phenomenon, we investigated whether HAD-B modulates inflammatory responses and explored the associated molecular mechanisms. The immunomodulatory activity of HAD-B in toll-like receptor-activated macrophages induced by lipopolysaccharide (LPS) was assessed by measuring nitric oxide (NO) and prostaglandin E2 (PGE2) levels. To identify the specific transcription factors (such as nuclear factor [NF]-jB and signaling enzymes) targeted by HAD-B, biochemical approaches, including kinase assays and immunoblot analysis, were additionally employed. HAD-B suppressed the production of PGE2 and NO in LPS-activated macrophages in a dose-dependent manner. Furthermore, the extract ameliorated HCl/EtOH-induced gastritis symptoms. Moreover, HAD-B significantly inhibited LPS-induced mRNA expression of inducible NO synthase and cyclooxygenase (COX)-2. Interestingly, marked inhibition of NF-jB and activating transcription factor was observed in the presence of HAD-B. Data from direct kinase assays and immunoblot analysis showed that HAD-B suppresses activation of the upstream signaling cascade involving spleen tyrosine kinase, Src, p38, c-Jun N-terminal kinase, and transforming growth factor b-activated kinase 1. Finally, kaempferol, but not quercetin or resveratrol was identified as a bioactive compound in HAD-B. Therefore, our results suggest that HAD-B possesses anti-inflammatory activity that contributes to its anticancer property.

show abstract

“…Chinese herbal medicine (CHM) has long been widely used in China [20]. Numerous studies have demonstrated the biological activity and therapeutic mechanism of CHM [21][22][23][24]. Recent studies show that certain Chinese herbs have renoprotective effects, improving GFR and decreasing proteinuria, especially in patients with microalbuminuria [25][26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Chinese herbal medicine Tangshen Formula Treatment For Type 2 Diabetic Kidney Disease in Early Stage : study protocol for a randomized controlled trial

Jin

Huang

Meng

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Diabetic kidney disease (DKD) is the main cause of end stage kidney disease (ESKD) and It has become a heavy economic and social burden due to its high prevalence and morbidity. The most effective strategy is that patients with DKD should be diagnosed and treated early. Preliminary studies showed the Chinese herbal Tangshen Formula (TSF) may delay the progression of DKD, reducing micro-and macro-albuminuria and improving renal function. We designed a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of TSF in patients with DKD. Methods/design: This trial is a thirteen-center, randomized, double-blind, placebo-controlled study. 623 participants will be randomized in a 1:1 ratio to an experiment group (TSF plus Losartan) and a control group (placebo plus Losartan). The trial cycle will last 24 weeks. The primary outcome will be the change in Urine microalbumin creatinine ratio （ ACR ） from baseline to week 24. The secondary outcome will be the change in the rate of progression into the clinical proteinuria period after intervention, the rate of urine microalbumin negative conversion, the rate of normal urinary microalbumin, doubling rate of baseline creatinine value and glomerular filtration rate (GFR) between the two groups. Safety in medication will also be evaluated. Discussion: We hypothesize that type 2 diabetic patients in early stage of DKD will benefit from TSF. If successful, this study will provide evidence-based recommendations for clinicians. Trial registration: ClinicalTrials.gov (NCT03009864) Keywords: Diabetes Kidney Disease, Traditional Chinese medicine, Treatment, Randomized controlled trial

show abstract

Anti-angiogenic effects of the water extract of HangAmDan (WEHAD), a Korean traditional medicine

Cited by 17 publications

References 22 publications

TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis

TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis

HangAmDan-B, an Ethnomedicinal Herbal Mixture, Suppresses Inflammatory Responses by Inhibiting Syk/NF-κB and JNK/ATF-2 Pathways

Chinese herbal medicine Tangshen Formula Treatment For Type 2 Diabetic Kidney Disease in Early Stage : study protocol for a randomized controlled trial

Contact Info

Product

Resources

About